Continental Chemicals Limited has scheduled a meeting of its Board of Directors for Friday, August 21, 2026, at 3:00 pm. The session will take place at the company’s registered office in Noida, Uttar Pradesh.

The primary agenda includes approving the draft of the Board's Report in compliance with the Companies Act. The Board will also determine the time, date, and place for the upcoming annual general meeting (AGM) and approve the draft notice for the event.

Key Agenda Items

The meeting will address several administrative and governance matters:

• Director Reappointment: The Board will appoint a director in place of Ms. Sunaina Chibba (DIN: 00370454), who retires by rotation. Being eligible, she offers herself for re-appointment.
• AGM Logistics: The Board will appoint a scrutinizer for the coming AGM.
• Share Transfer Books: The meeting will consider the closure of the Register of Members and the Share Transfer Books in compliance with the Companies Act.

The intimation was issued pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015. Sakshi Dhawan, Company Secretary, signed the communication dated August 14, 2026.

Continental Chemicals Limited has submitted a statement of deviation under Regulation 32 of the SEBI (LODR) Regulations, 2015, confirming that there has been no variation in the utilization of funds raised through its preferential issue for the quarter ended June 30, 2026. The filing indicates that the company strictly adhered to the originally disclosed objects for the funds, which were designated for working capital requirements, with no deviations or variations reported during the period.

The regulatory submission, dated August 11, 2026, and signed by Company Secretary Sakshi Dhawan, provides transparency regarding the status of the capital raised on October 14, 2019. According to the annexure attached to the filing, the total amount raised was ₹1,62,50,000. The document explicitly states that the funds have been fully utilized in the quarter ended December 31, 2023, meaning no further utilization or deviation occurred in the subsequent quarters, including the current reporting period.

The audit committee of Continental Chemicals reviewed and approved the statement, affirming compliance with the regulatory requirements. No monitoring agency was appointed for this specific fundraising activity, as indicated in the filing. Furthermore, there were no comments from auditors regarding any irregularities or deviations, reinforcing the clean status of the fund utilization.

The filing clarifies that a deviation or variation could imply changes in the objects for which funds were raised, discrepancies in the amount utilized versus what was disclosed, or changes in contract terms. None of these scenarios applied to Continental Chemicals’ recent reporting. The company’s managing director, Naresh Kumar Chibba, also endorsed the document, ensuring executive accountability for the disclosure.

What the Numbers Show

The complete utilization of the ₹1,62,50,000 by December 31, 2023, suggests that the working capital needs associated with this specific fundraising event were met within approximately four years of the capital raise. With zero deviation recorded in Q1FY26, the company demonstrates disciplined adherence to its initial funding objectives, eliminating any regulatory concerns regarding misallocation or unauthorized use of investor capital for this particular tranche.